B-cel in multiple sclerose

1. www.atlasofms.org [2] [geraadpleegd 31/01/21]
2. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25-36.
3. Kinnunen T, Chamberlain N, Morbach H, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013;123(6):2737-41.
4. Farh, Kyle Kai-How, et al. "Genetic and epigenetic fine mapping of causal autoimmune disease variants." Nature 518.7539 (2015): 337-343.
5. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019 Sep 27;365(6460):eaav7188.
6. Rawlings DJ, Metzler G, Wray-Dutra M, et al. Altered B cell signalling in autoimmunity. Nat Rev Immunol. 2017;17(7):421-36.
7. Bar-Or A, Pender MP, Khanna R, et al. Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends Mol Med. 2020;26(3):296-310.
8. Greenfield AL, Hauser SL. B Cell Therapy for Multiple Sclerosis: Entering an Era. Ann Neurol. 2018;83(1):13-26.
9. Moreno Torres I, García-Merino A. Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Rev Neurother. 2017;17(4):359-71.
10. van Langelaar J, Rijvers L, Smolders J, et al. B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers. Front Immunol. 2020;11:760.
11. Bruck W, Gold R, Lund BT, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 2013;70(10):1315–24.
12. International Multiple Sclerosis Genetics Consortium*†, et al. "Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility." Science 365.6460 (2019): eaav7188.
13. Bar-Or, Amit, et al. "Epstein–Barr virus in multiple sclerosis: theory and emerging immunotherapies." Trends in molecular medicine 26.3 (2020): 296-310.
14. Jelcic, Ivan, et al. "Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis." Cell 175.1 (2018): 85-100.
15. Sabatino, Joseph J., Anne-Katrin Pröbstel, and Scott S. Zamvil. "B cells in autoimmune and neurodegenerative central nervous system diseases." Nature Reviews Neuroscience 20.12 (2019): 728-745.
16. Wang, Jian, et al. "HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis." Cell 183.5 (2020): 1264-1281.
17. Farh, Kyle Kai-How, et al. "Genetic and epigenetic fine mapping of causal autoimmune disease variants." Nature 518.7539 (2015): 337-343.
18. van Langelaar, Jamie, et al. "The association of Epstein‐Barr virus infection with CXCR3+ B‐cell development in multiple sclerosis: impact of immunotherapies." European journal of immunology 51.3 (2021): 626-633.
19. Hauser, Stephen L., et al. "B-cell depletion with rituximab in relapsing–remitting multiple sclerosis." New England Journal of Medicine 358.7 (2008): 676-688.
20. Bar‐Or, Amit, et al. "Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?." Annals of neurology 67.4 (2010): 452-461.
21. Li, Rui, Kristina R. Patterson, and Amit Bar-Or. "Reassessing B cell contributions in multiple sclerosis." Nature immunology 19.7 (2018): 696-707.
22. Tysabri | European Medicines Agency (europa.eu) [3]
23. Lemtrada | European Medicines Agency (europa.eu) [4]
24. Mavenclad | European Medicines Agency (europa.eu) [5]
25. SmPC Gilenya [6], 9 mei 2023
26. SmPC Mayzent [7], 12 januari 2023
27. Zeposia | European Medicines Agency (europa.eu) [8]
28. Tecfidera | European Medicines Agency (europa.eu) [9]
29. Dendrou, Calliope A., Lars Fugger, and Manuel A. Friese. "Immunopathology of multiple sclerosis." Nature Reviews Immunology 15.9 (2015): 545-558.
30. Rijvers, Liza, et al. "The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis." European journal of immunology 48.11 (2018): 1861-1871.
31. Rijvers, Liza, et al. "The Role of Autoimmunity-Related Gene CLEC16A in the B Cell Receptor–Mediated HLA Class II Pathway." The Journal of Immunology 205.4 (2020): 945-956.
32. Van Langelaar, Jamie, et al. "T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention." Brain 141.5 (2018): 1334-1349.
33. Jelcic, Ivan, et al. "Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis." Cell 175.1 (2018): 85-100.
34. van Langelaar, Jamie, et al. "Induction of brain‐infiltrating T‐bet–expressing B cells in multiple sclerosis." Annals of neurology 86.2 (2019): 264-278.
35. Kearney, Hugh, et al. "Cervical cord lesion load is associated with disability independently from atrophy in MS." Neurology 84.4 (2015): 367-373.
36. Calabrese, Massimiliano, Massimo Filippi, and Paolo Gallo. "Cortical lesions in multiple sclerosis." Nature Reviews Neurology 6.8 (2010): 438-444.
37. Hao, Yi, et al. "A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice." Blood, The Journal of the American Society of Hematology 118.5 (2011): 1294-1304.
38. Da Mesquita, Sandro, Zhongxiao Fu, and Jonathan Kipnis. "The meningeal lymphatic system: a new player in neurophysiology." Neuron 100.2 (2018): 375-388.
39. Strazielle, Nathalie, and Jean-Francois Ghersi-Egea. "Choroid plexus in the central nervous system: biology and physiopathology." Journal of neuropathology & experimental neurology 59.7 (2000): 561-574.
40. Engelhardt, Britta, Karen Wolburg‐Buchholz, and Hartwig Wolburg. "Involvement of the choroid plexus in central nervous system inflammation." Microscopy research and technique 52.1 (2001): 112-129.
41. Howell, Owain W., et al. "Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis." Brain 134.9 (2011): 2755-2771.
42. Ocrevus | European Medicines Agency (europa.eu) [10]
43. SmPC Kesimpta [11], 9 feb 2023
44. Lublin, Fred D., et al. "Defining the clinical course of multiple sclerosis: the 2013 revisions." Neurology 83.3 (2014): 278-286.